Q2 2018 13F Holders as of 30 Jun 2018
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
52,764,512
-
Share change
-
+5,915,810
-
Total reported value
-
$728,147,459
-
Put/Call ratio
-
142%
-
Price per share
-
$13.80
-
Number of holders
-
112
-
Value change
-
+$98,153,369
-
Number of buys
-
71
-
Number of sells
-
51
Institutional Holders of ENDOCYTE INC - COM (ECYT) as of Q2 2018
As of 30 Jun 2018,
ENDOCYTE INC - COM (ECYT) was held by
112 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
52,764,512 shares.
The largest 10 holders included
venBio Select Advisor LLC, RA CAPITAL MANAGEMENT, LLC, BlackRock Inc., VHCP Management II, LLC, Partner Fund Management, L.P., VANGUARD GROUP INC, PRICE T ROWE ASSOCIATES INC /MD/, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), BAKER BROS. ADVISORS LP, and CITADEL ADVISORS LLC.
This page lists
112
institutional shareholders reporting positions in this security
for the Q2 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.